专业仿製药市场规模、份额和趋势分析报告:按类型(注射剂,口服),应用(肿瘤学,炎症性疾病,丙型肝炎),用途(专业/零售),地区,细分市场预测2022-2030
市场调查报告书
商品编码
1114057

专业仿製药市场规模、份额和趋势分析报告:按类型(注射剂,口服),应用(肿瘤学,炎症性疾病,丙型肝炎),用途(专业/零售),地区,细分市场预测2022-2030

Specialty Generics Market Size, Share & Trends Analysis Report By Type (Injectables, Oral Drugs), By Application (Oncology, Inflammatory Conditions, Hepatitis C), By End-use (Specialty, Retail), By Region, And Segment Forecasts, 2022 - 2030

出版日期: | 出版商: Grand View Research | 英文 101 Pages | 商品交期: 2-10个工作天内

价格

特种仿製药的市场增长和趋势

Grand View Research, Inc. 的一项新研究显示,到 2030 年,全球特种仿製药市场预计将达到 1487 亿美元。

从 2022 年到 2030 年,市场预计将以 9.2% 的复合年增长率增长。市场增长主要受到产品批准的增加和多发性硬化症等复杂慢性病患病率上升的推动。

2022年4月,雷迪博士实验室在美国推出甲基强的松龙琥珀酸钠注射液,用于治疗关节炎、血液疾病和某些罕见癌症患者。此外,2022 年 6 月,Elixir 启动了旨在管理专业仿製药定价的 Copay 解决方案增强计划。该计划允许符合条件的患者以零成本获得特殊药物的仿製药。因此,新的低价仿製药注射剂的推出和此类项目的可用性预计将推动市场增长。

仿製药安全、有效且耐受性良好,由于报销增加和更容易获得,导致处方率更高。根据密歇根大学人力资源福利办公室年度报告(2021 年),2020 年有 1360 例特殊仿製药,如醋酸格拉替雷(copaxone/glatopa)、特立氟胺(Auvio)和芬戈莫德(Gilenya),2021 年约有 1,383索赔将得到解决,这意味着多发性硬化症患者的治疗增加了 1.7%。

但是,与特殊仿製药相关的高成本可能会阻碍其广泛采用。无法吸引患者使用该药,公司获得了没有仿製药竞争对手的非专利药物的营销权,以及目标患者人群狭窄,这些都促成了随后的产品价格上涨。根据密歇根大学处方药计划处方集报告,专业仿製药的平均成本超过每人每月 4,500 美元,而仿製药处方的平均成本为 17-22 美元。

特殊仿製药市场报告亮点

按类型划分,注射剂细分市场在 2021 年占据市场主导地位。与口服药物相比,由于其长效和即时吸收的高处方率,预计在预测期内将保持其主导地位。

通过应用,由于癌症患病率的增加,预计癌症区域在预测期内将出现显着增长。据 Globocan 称,预计未来 20 年全球新发癌症病例数将达到 2840 万例。

就最终用户而言,专业药房部分在 2021 年占据了市场主导地位,因为其具有及时交付、优化患者访问和有效分销管理等特点。

按地区划分,由于存在对新产品批准的支持性监管政策,北美在 2021 年主导了市场。美国 FDA 根据 Hatch-Waxman 法案引入了仿製药用户费用修正案 (GDUFA),以加快新仿製药的批准

目录

第一章调查方法及范围

  • 市场细分
    • 估计/预测时间表
  • 调查方法
  • 信息采购
    • 购买的数据库
    • GVR 内部数据库
    • 辅助信息
    • 初步调查
    • 初步调查的内容
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 型号详情
    • 商品流向分析
      • 方法 1:商品流通方法
      • 方法 2:使用自下而上的方法估算国别市场
  • 全球市场:CAGR 计算
  • 调查假设
  • 辅助信息列表
  • 主要信息列表
  • 缩写列表
  • 目的

第 2 章执行摘要

  • 市场概况

第 3 章市场变量、趋势和范围

  • 市场系列展望
    • 母公司市场展望
  • 绘製渗透率和增长前景
  • 监管和报销框架
  • 市场变量分析
    • 市场驱动因素分析
      • 专利已过期的特殊药物增加
      • 对低成本仿製药的需求不断增长
      • 慢性病患病率增加
      • 更加註重降低医疗保健费用
    • 市场约束分析
      • 与特殊仿製药相关的高成本
      • 新药上市延迟
  • 行业分析工具
    • 波特五力分析
    • PESTEL 分析
  • 管道分析

第 4 章专业仿製药市场 - 细分分析,按类型,2018-2030 年(十亿美元)

  • 专业通用市场:类型变化分析
  • 注入
  • 口服药
  • 其他

第 5 章专业仿製药市场 - 按应用分列的细分分析,2018-2030 年(十亿美元)

  • 专业仿製药市场:应用波动分析
  • 肿瘤学
  • 炎症状况
  • 多发性硬化症
  • 丙型肝炎
  • 其他

第 6 章。专业仿製药市场 - 细分分析,按最终用途,2018-2030 年(十亿美元)

  • 专业仿製药市场:最终用途变化分析
  • 专业药房
  • 零售药房
  • 医院药房

第 7 章。专业仿製药市场 - 2018-2030 年各地区细分分析(十亿美元)

  • 2021 年和 2030 年按地区分列的特殊仿製药市场、市场份额
    • 北美
      • 美国
      • 加拿大
    • 欧洲
      • 英国
      • 德国
      • 法国
      • 西班牙
      • 意大利
    • 亚太地区
      • 日本
      • 中国
      • 印度
      • 澳大利亚
      • 韩国
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
    • 中东和非洲
      • 南非
      • 沙特阿拉伯
      • 阿拉伯联合酋长国

第 8 章专业通用市场竞争分析

  • 分析重大交易和战略联盟
    • 推出新产品
    • 併购
    • 伙伴关係和战略合作
    • 会议和活动
  • 公司分类
    • 市场差异化因素
    • 创新者
    • 市场领导者
  • 供应商情况
    • 主要分销商和渠道合作伙伴列表
    • 主要客户
  • 热图分析
  • 上市公司
    • 2021 年主要参与者的市场份额分析
    • 公司市场分析
  • 私人公司
    • 主要初创公司列表
    • 本地网络地图
  • 公司简介
    • 梯瓦製药工业有限公司
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • Viatris Inc.
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • 诺华公司(Sandoz International GmbH)
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • 费森尤斯卡比巴西有限公司
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • 马林克罗特
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • Bausch Health Companies Inc.(Valeant Pharmaceuticals International, Inc.)
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • STADA Arzneimittel AG
      • 公司简介
      • 财务表现
      • 产品基准
    • 远籐製药公司
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • Apotex 公司
      • 公司简介
      • 产品基准
      • 战略举措
    • 太阳药业有限公司
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • 雷迪博士实验室有限公司
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • Hikma Pharmaceuticals PLC
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
Product Code: GVR-1-68038-629-5

Specialty Generics Market Growth & Trends:

The global specialty generics market size is expected to reach USD 148.7 billion by 2030, according to a new study by Grand View Research, Inc. The market is expected to expand at a CAGR of 9.2% from 2022 to 2030. The growth in the market is largely driven by increasing product approvals and the rising prevalence of complex chronic diseases, such as multiple sclerosis.

In April 2022, Dr. Reddy's Laboratories launched a methylprednisolone sodium succinate injection in the U.S. for the treatment of patients with arthritis, blood disorders, and certain rare cancers. Furthermore, in June 2022, Elixir launched copay solutions enhancement program for the management of specialty generic medication prices. Under this program, an eligible patient receives a generic version of specialty medication at zero cost. Thus, the launch of new low-cost generic injectables and the availability of such programs is projected to fuel market growth.

Increased claim settlements and availability of specialty generic drugs increase their prescription rates due to the high safety, efficacy, and tolerability associated with them. According to the Human Resources Benefits Office University of Michigan annual report (2021), around 1,383 claims were settled for specialty generic drugs such as glatiramer acetate (Copaxone/Glatopa), teriflunomide (Aubagio), and fingolimod (Gilenya) in 2021, compared to 1,360 in 2020, with a rise of 1.7% for the treatment of patients with multiple sclerosis.

However, high costs associated with specialty generics may hamper their uptake. The lack of ability to attract patients toward drugs, marketing rights acquired by companies for off-patent drugs with no generic competition, and small target patient pool, subsequently increases the prices of products. According to the University of Michigan Prescription Drug Plan Formulary report, the average cost of specialty generic is over USD 4,500 monthly per person, compared to USD 17 to 22 for a generic prescription.

Specialty Generics Market Report Highlights:

  • Based on type, the injectables segment dominated the market in 2021. It is estimated to maintain its dominance during the forecast period due to its high prescription rate on account of long-term effects, and immediate absorption compared to oral drugs
  • Based on application, the oncology segment is expected to witness significant growth during the projection period owing to the increasing prevalence of cancer. According to Globocan, the number of new cancer cases is anticipated to reach 28.4 million within the next two decades worldwide
  • On the basis of end-use, the specialty pharmacy segment dominated the market in 2021 owing to features like timely delivery, optimized patient access, and effective distribution management
  • Based on region, North America dominated the market in 2021 due to the presence of supportive regulatory policies regarding the approval of new products. The U.S. FDA introduced Generic Drug User Fee Amendments (GDUFA) under the Hatch-Waxman act to quicken the approval of new generic drugs

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation
    • 1.1.1 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Research Assumptions
  • 1.9 List of Secondary Sources
  • 1.10 List of Primary Sources
  • 1.11 List of Abbreviations
  • 1.12 Objectives
    • 1.12.1 Objective 1
    • 1.12.2 Objective 2
    • 1.12.3 Objective 3
    • 1.12.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Regulatory and Reimbursement Framework
  • 3.4 Market Variable Analysis
    • 3.4.1 Market driver analysis
      • 3.4.1.1 Rising number of off-patent specialty drugs
      • 3.4.1.2 Escalating demand for low-cost generic specialty drugs
      • 3.4.1.3 Increasing prevalence of chronic disease
      • 3.4.1.4 Increasing emphasis to cut down healthcare expenditure
    • 3.4.2 Market restraint analysis
      • 3.4.2.1 High costs associated with specialty generics
      • 3.4.2.2 Delay in new drug launches
  • 3.5 Industry Analysis Tools
    • 3.5.1 Porter's five forces analysis
    • 3.5.2 PESTEL Analysis
  • 3.6 Pipeline Analysis

Chapter 4 Specialty Generics Market - Segment Analysis, by Type, 2018 - 2030 (USD Billion)

  • 4.1 Specialty Generics Market: Type Movement Analysis
  • 4.2 Injectables
    • 4.2.1 Injectables market, 2018 - 2030 (USD Billion)
  • 4.3 Oral Drugs
    • 4.3.1 Oral drugs market, 2018 - 2030 (USD Billion)
  • 4.4 Others
    • 4.4.1 Others market, 2018 - 2030 (USD Billion)

Chapter 5 Specialty generics Market - Segment Analysis, by Application, 2018 - 2030 (USD Billion)

  • 5.1 Specialty Generics Market: Application Movement Analysis
  • 5.2 Oncology
    • 5.2.1 Oncology market, 2018 - 2030 (USD Billion)
  • 5.3 Inflammatory Conditions
    • 5.3.1 Inflammatory conditions market, 2018 - 2030 (USD Billion)
  • 5.4 Multiple Sclerosis
    • 5.4.1 Multiple sclerosis market, 2018 - 2030 (USD Billion)
  • 5.5 Hepatitis C
    • 5.5.1 Hepatitis C market, 2018 - 2030 (USD Billion)
  • 5.6 Others
    • 5.6.1 Others market, 2018 - 2030 (USD Billion)

Chapter 6 Specialty generics Market - Segment Analysis, by End-Use, 2018 - 2030 (USD Billion)

  • 6.1 Specialty Generics Market: End-Use Movement Analysis
  • 6.2 Specialty Pharmacy
    • 6.2.1 Specialty pharmacy market, 2018 - 2030 (USD Billion)
  • 6.3 Retail Pharmacy
    • 6.3.1 Retail pharmacy market, 2018 - 2030 (USD Billion)
  • 6.4 Hospital Pharmacy
    • 6.4.1 Hospital pharmacy market, 2018 - 2030 (USD Billion)

Chapter 7 Specialty generics Market - Segment Analysis, By Region, 2018 - 2030 (USD Billion)

  • 7.1 Specialty Generics Market, Market Share by Region, 2021 & 2030
    • 7.1.1 North America
      • 7.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Billion)
      • 7.1.1.2 U.S.
      • 7.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Billion)
      • 7.1.1.3 Canada
      • 7.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.1.2 Europe
      • 7.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Billion)
      • 7.1.2.2 U.K.
      • 7.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Billion)
      • 7.1.2.3 Germany
      • 7.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Billion)
      • 7.1.2.4 France
      • 7.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Billion)
      • 7.1.2.5 Spain
      • 7.1.2.5.1 Spain market estimates and forecast, 2018 - 2030 (USD Billion)
      • 7.1.2.6 Italy
      • 7.1.2.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.1.3 Asia Pacific
      • 7.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Billion)
      • 7.1.3.2 Japan
      • 7.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Billion)
      • 7.1.3.3 China
      • 7.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Billion)
      • 7.1.3.4 India
      • 7.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Billion)
      • 7.1.3.5 Australia
      • 7.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Billion)
      • 7.1.3.6 South Korea
      • 7.1.3.6.1 South Korea market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.1.4 Latin America
      • 7.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Billion)
      • 7.1.4.2 Brazil
      • 7.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Billion)
      • 7.1.4.3 Mexico
      • 7.1.4.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Billion)
      • 7.1.4.4 Argentina
      • 7.1.4.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.1.5 Middle East and Africa
    • 7.1.6 Middle East and Africa market estimates and forecast, 2018 - 2030 (USD Billion)
      • 7.1.6.1 South Africa
      • 7.1.6.1.1 South Africa market estimates and forecast, 2018 - 2030 (USD Billion)
      • 7.1.6.2 Saudi Arabia
      • 7.1.6.2.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Billion)
      • 7.1.6.3 UAE
      • 7.1.6.3.1 UAE market estimates and forecast, 2018 - 2030 (USD Billion)

Chapter 8 Specialty Generics Market-Competitive Analysis

  • 8.1 Major Deals and Strategic Alliances Analysis
    • 8.1.1 New Product Launch
    • 8.1.2 Mergers and Acquisitions
    • 8.1.3 Partnerships and Strategic Collaborations
    • 8.1.4 Conferences and Campaigns
  • 8.2 Company Categorization
    • 8.2.1 Market Differentiators
    • 8.2.2 Innovators
    • 8.2.3 Market Leaders
  • 8.3 Vendor Landscape
    • 8.3.1 List of key distributors and channel partners
    • 8.3.2 Key customers
  • 8.4 Heat map analysis
  • 8.5 Public Companies
    • 8.5.1 Key company market share analysis, 2021
    • 8.5.2 Company Market Position Analysis
  • 8.6 Private Companies
    • 8.6.1 List of key emerging companies
    • 8.6.2 Regional Network Map
  • 8.7 Company Profiles
    • 8.7.1 Teva Pharmaceutical Industries Ltd
      • 8.7.1.1 Company overview
      • 8.7.1.2 Financial performance
      • 8.7.1.3 Product benchmarking
      • 8.7.1.4 Strategic initiatives
    • 8.7.2 Viatris Inc.
      • 8.7.2.1 Company overview
      • 8.7.2.2 Financial performance
      • 8.7.2.3 Product benchmarking
      • 8.7.2.4 Strategic initiatives
    • 8.7.3 Novartis AG (Sandoz International GmbH)
      • 8.7.3.1 Company overview
      • 8.7.3.2 Financial performance
      • 8.7.3.3 Product benchmarking
      • 8.7.3.4 Strategic initiatives
    • 8.7.4 Fresenius Kabi Brasil Ltda
      • 8.7.4.1 Company overview
      • 8.7.4.2 Financial performance
      • 8.7.4.3 Product benchmarking
      • 8.7.4.4 Strategic initiatives
    • 8.7.5 Mallinckrodt
      • 8.7.5.1 Company overview
      • 8.7.5.2 Financial performance
      • 8.7.5.3 Product benchmarking
      • 8.7.5.4 Strategic initiatives
    • 8.7.6 Bausch Health Companies Inc. (Valeant Pharmaceuticals International, Inc.)
      • 8.7.6.1 Company overview
      • 8.7.6.2 Financial performance
      • 8.7.6.3 Product benchmarking
      • 8.7.6.4 Strategic initiatives
    • 8.7.7 STADA Arzneimittel AG
      • 8.7.7.1 Company overview
      • 8.7.7.2 Financial performance
      • 8.7.7.3 Product benchmarking
    • 8.7.8 Endo Pharmaceuticals Inc.
      • 8.7.8.1 Company overview
      • 8.7.8.2 Financial performance
      • 8.7.8.3 Product benchmarking
      • 8.7.8.4 Strategic initiatives
    • 8.7.9 Apotex Corp.
      • 8.7.9.1 Company overview
      • 8.7.9.2 Product benchmarking
      • 8.7.9.3 Strategic initiatives
    • 8.7.10 Sun Pharmaceutical Industries Ltd.
      • 8.7.10.1 Company overview
      • 8.7.10.2 Financial performance
      • 8.7.10.3 Product benchmarking
      • 8.7.10.4 Strategic initiatives
    • 8.7.11 Dr. Reddy's Laboratories Ltd
      • 8.7.11.1 Company overview
      • 8.7.11.2 Financial performance
      • 8.7.11.3 Product benchmarking
      • 8.7.11.4 Strategic initiatives
    • 8.7.12 Hikma Pharmaceuticals PLC
      • 8.7.12.1 Company overview
      • 8.7.12.2 Financial performance
      • 8.7.12.3 Product benchmarking
      • 8.7.12.4 Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 Regulatory framework
  • Table 4 Leading market players anticipated to witness highest growth
  • Table 5 List of key distributors and compounding pharmacies
  • Table 6 North America Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 7 North America Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 8 North America Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 9 U.S. Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 10 U.S. Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 11 U.S. Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 12 Canada Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 13 Canada Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 14 Canada Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 15 Europe Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 16 Europe Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 17 Europe Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 18 U.K. Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 19 U.K. Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 20 U.K. Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 21 Germany Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 22 Germany Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 23 Germany Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 24 France Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 25 France Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 26 France Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 27 Italy Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 28 Italy Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 29 Italy Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 30 Spain Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 31 Spain Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 32 Spain Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 33 Asia Pacific Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 34 Asia Pacific Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 35 Asia Pacific Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 36 Japan Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 37 Japan Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 38 Japan Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 39 China Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 40 China Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 41 China Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 42 India Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 43 India Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 44 India Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 45 Australia Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 46 Australia Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 47 Australia Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 48 South Korea Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 49 South Korea Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 50 South Korea Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 51 Latin America Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 52 Latin America Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 53 Latin America Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 54 Brazil Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 55 Brazil Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 56 Brazil Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 57 Mexico Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 58 Mexico Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 59 Mexico Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 60 Argentina Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 61 Argentina Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 62 Argentina Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 63 Middle East & Africa Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 64 Middle East & Africa Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 65 Middle East & Africa Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 66 South Africa Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 67 South Africa Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 68 South Africa Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 69 Saudi Arabia Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 70 Saudi Arabia Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 71 Saudi Arabia Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 72 UAE Specialty Generics Market, By Type, 2018 - 2030 (USD Billion)
  • Table 73 UAE Specialty Generics Market, By Application, 2018 - 2030 (USD Billion)
  • Table 74 UAE Specialty Generics Market, By End-use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Specialty Generics Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Information Procurement
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 QFD Modeling for Market Share Assessment
  • Fig. 8 Market Formulation & Validation
  • Fig. 9 Market Summary
  • Fig. 10 Penetration & Growth Prospect Mapping
  • Fig. 11 Market Driver Impact Analysis (Current & future impact)
  • Fig. 12 Market Restraint Impact Analysis (Current & future impact)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Specialty generics market type outlook: Key takeaways
  • Fig. 15 Injectables market, 2018 - 2030 (USD Billion)
  • Fig. 16 Oral drugs market, 2018 - 2030 (USD Billion)
  • Fig. 17 Others market, 2018 - 2030 (USD Billion)
  • Fig. 18 Specialty generics market application outlook: Key takeaways
  • Fig. 19 Specialty generics market: Application movement analysis
  • Fig. 20 Oncology market, 2018 - 2030 (USD Billion)
  • Fig. 21 Inflammatory conditions market, 2018 - 2030 (USD Billion)
  • Fig. 22 Multiple sclerosis market, 2018 - 2030 (USD Billion)
  • Fig. 23 Hepatitis C market, 2018 - 2030 (USD Billion)
  • Fig. 24 Others market, 2018 - 2030 (USD Billion)
  • Fig. 25 Specialty generics market end-use outlook: Key takeaways
  • Fig. 26 Specialty generics market: End-use movement analysis
  • Fig. 27 Specialty pharmacy market, 2018 - 2030 (USD Billion)
  • Fig. 28 Retail pharmacy market, 2018 - 2030 (USD Billion)
  • Fig. 29 Hospital pharmacy market, 2018 - 2030 (USD Billion)
  • Fig. 30 Specialty generics: Regional Outlook
  • Fig. 31 Regional outlook, 2021 & 2030
  • Fig. 32 North America
  • Fig. 33 North America market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 34 U.S.
  • Fig. 35 U.S. market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 36 Canada
  • Fig. 37 Canada market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 38 Europe
  • Fig. 39 Europe market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 40 U.K.
  • Fig. 41 U.K. market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 42 Germany
  • Fig. 43 Germany market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 44 France
  • Fig. 45 France market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 46 Spain
  • Fig. 47 Spain market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 48 Italy
  • Fig. 49 Italy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 50 Asia Pacific
  • Fig. 51 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 52 Japan
  • Fig. 53 Japan market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 54 China
  • Fig. 55 China market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 56 India
  • Fig. 57 India market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 58 Australia
  • Fig. 59 Australia market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 60 South Korea
  • Fig. 61 South Korea market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 62 Latin America
  • Fig. 63 Latin America market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 64 Brazil
  • Fig. 65 Brazil market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 66 Mexico
  • Fig. 67 Mexico market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 68 Argentina
  • Fig. 69 Argentina market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 70 Middle East & Africa
  • Fig. 71 MEA market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 72 South Africa
  • Fig. 73 South Africa market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 74 Saudi Arabia
  • Fig. 75 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 76 UAE
  • Fig. 77 UAE market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 78 Market differentiators
  • Fig. 79 Heat Map Analysis
  • Fig. 80 Key company market share analysis, 2021
  • Fig. 81 Company market position analysis
  • Fig. 82 Company market position analysis